ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness) is a study comparing the effectiveness of two daily doses of aspirin widely used to prevent heart attacks and strokes in individuals living with heart disease.
Funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (Contract Number: ASP-1502-27079), ADAPTABLE spans the U.S. and is the first demonstration project to be conducted through PCORnet, the National Patient-Centered Clinical Research Network. PCORnet is a PCORI-funded initiative designed to improve the nation’s capacity to conduct comparative clinical effectiveness research.
In Chicagoland, ADAPTABLE is an offshoot of CAPriCORN, with CHIP Director Abel Kho as the clinical principle investigator. We’re implementing a recruitment strategy that engages patients during office visits as well as in non-clinical settings in underserved communities. Community recruitment partners include Sinai Urban Health Institute and Pastors 4 PCOR.
For more information, visit theaspirinstudy.com
Charon Gladfelter, Research Project Coordinator
Collaborators: Chicago Community Trust, Duke University, Pastors4PCOR, and Sinai Urban Health Institute
CHiP collaborators are part of the public, private and nonprofit sectors and have an interest in working toward a world where health outcomes are improved because data is used effectively.Get in Touch